Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production

Area of Science:

• Immunology
• Molecular Biology
• Allergy Research

Background:

• Specialized proresolving mediators (SPMs) are bioactive molecules that resolve inflammation.
• Previous research showed SPMs, including resolvin D1 (RvD1) and 17-hydroxydocosahexaenoic acid (17-HDHA), enhance IgG antibody production.
• The role of SPMs in regulating human B-cell IgE production, crucial in allergic diseases, was unknown.

Purpose of the Study:

• To investigate the effect of various SPMs on human B-cell IgE production.
• To determine if SPMs can modulate IgE synthesis in the context of allergic inflammation.

Main Methods:

• Human B cells were treated with a panel of SPMs.
• IgE production and B-cell differentiation into IgE-secreting cells were measured.
• Mechanisms involving epsilon germline transcript and transcriptional repressor B-cell lymphoma 6 (BCL-6) were analyzed.

Main Results:

• 17-hydroxydocosahexaenoic acid (17-HDHA) and resolvin D1 (RvD1) significantly inhibited IgE production by human B cells.
• These SPMs suppressed the differentiation of naive B cells into IgE-secreting cells by blocking the epsilon germline transcript.
• The inhibitory effect was specific to IgE, as IgM and IgG production were unaffected.
• SPMs stabilized B-cell lymphoma 6 (BCL-6), which interfered with STAT6 binding to the epsilon germline transcript promoter.

Conclusions:

• Certain SPMs, specifically 17-HDHA and RvD1, inhibit human IgE production.
• These SPMs selectively target IgE-producing B cells without broad immunosuppression.
• This finding identifies SPMs as a novel class of potential therapeutics for IgE-driven diseases like asthma and allergies.